Breast Cancer Treatment Market Projected To Grow With Significant CAGR Over The Forecast Period

28/mag/2018 11:01:31 pbi Contatta l'autore

Questo comunicato è stato pubblicato più di 6 mesi fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Breast Cancer Treatment Market Projected To Grow With Significant CAGR Over The Forecast Period

Breast cancer is a disease where uncontrolled growth of malignant cells in the breast tissue that is most commonly occurs in female than men. The common signs and symptoms associated with breast cancer include change in the breast shape, lumps in the breast, dimpling of skin, and red scaly patches on the skin. Treatment of breast cancer depends on various factors such as the type of breast cancer, the size of a tumor, stage of breast cancer and the grade of cancer cells. Breast cancer can be treated by various therapies such as radiation therapy, chemotherapy, hormone therapy, targeted therapy and bone-directed therapy.  The breast cancer commonly occurs due to drinking alcohol, being female, obesity, ionizing radiation, genetics and older age, etc. The breast cancer is diagnosed by taking a biopsy of lump. After the diagnosis, further tests are carried to determine the cancer stage and suitable treatment for the disease.

 

The global breast cancer treatment market is expected to increase with significant rate due to increasing breast cancer cases. Rising awareness about breast cancer stages and treatment, government initiatives, and improving healthcare infrastructure are driving the breast cancer treatment market. Furthermore, increased investments in R & D, development of targeted drug delivery systems, and advancement in cancer biology & pharmacology will boost the breast cancer treatment market. However, drug development challenges in developing countries, long-term side effects of drugs, high costs associated with drug development, stringent regulatory guidelines, and patent expiry of drugs might hamper the growth of breast cancer treatment market.

 

Free sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-breast-cancer-treatment-market/#ulp-4H8Z4LpNMLEuOnnx

 

The breast cancer treatment market is categorized on the basis of - 

1.      Drug class

·         Anthracyclines

·         Antimetabolites

·         Epothilones

·         Taxanes

·         Alkylating agents

·         Hormonal therapy

·         Aromatase inhibitors

·         Selective estrogen-receptor modulators

2.     End-users

·         Hospital, retail and online pharmacies 

 

Free TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-breast-cancer-treatment-market/#ulp-c654SbFYO64MsOhu

 

And lastly on the basis of geographical regions, the global breast cancer drugs market has five major regions- North America, Europe, Latin America, Middle East and Africa and Asia-Pacific. North America dominates the breast cancer treatment market due to increase cases of breast cancer disease, increase in old age female population, and favorable government initiatives for the treatment. Europe holds a major share in breast cancer treatment market owing to rise in the prevalence and incidence of breast cancer cases. Most of the pharmaceutical companies in breast cancer treatment market are focused on R & D, strategic collaborations, acquisitions & mergers, and product launches for the development in the breast cancer treatment market.

 

Ask Analyst for Full Information about this report @

https://www.precisionbusinessinsights.com/market-reports/global-breast-cancer-treatment-market/#ulp-14mlyhjMGhVjZqa3

 

Some of the key players in breast cancer drugs market are AstraZeneca (U.K.), GlaxoSmithKline plc (U.K.), Eli Lilly and Company (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Sanofi (France), Pfizer, Inc. (U.S.). Sun Pharmaceutical Industries Ltd (India), Actavis, Inc. (U.S.), Bayer AG (Germany), Teva Pharmaceutical Industries. Ltd. (Israel), Puma Biotechnology, Inc. (U.S.), and OncoGenex Pharmaceuticals Inc. (U.S.) to name a few. In 2017, U.S. FDA approved the Puma Biotechnology’s Nerlynx (Neratinib) for the treatment of HER2-positive breast cancer in early stage. And in the same year, AstraZeneca received an approval from European Commission (EC) for Faslodex (fulvestrant) for the breast cancer treatment.

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/global-breast-cancer-treatment-market/

 

 

About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,

Kemp House,

152 – 160 City Road,

London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US):+1-866-598-1553

Website @https://www.precisionbusinessinsights.com

 

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl